
HC15: Framework oncology and staging
Tumor grading
A tumor grade reflects intrinsic biological behavior of tumors. In general, a low grade is less aggressive. It is necessary to grade a tumor for treatment and prognosis:
- Lower grade → better prognosis
- Higher grade → worse prognosis
Tumors are graded based on the microscopic appearance of cancer cells. Dependent on the tumor, there are 2-4 degrees of severity. An example is:
- GX: grade cannot be assessed
- Undetermined grade
- G1: Well-differentiated
- Low grade
- G2: moderately differentiated
- Intermediate grade
- G3: poorly differentiated
- High grade
- G4: undifferentiated
- High grade
Breast cancer grades:
The amount of grades differs per tumor type. In case of breast cancer, there are only 3 grades. These grades can be linked to the expected 5 year survival rates:
- Total: 91-95%
- Grade I: 75%
- Grade II: 53%
- Grade III: 31%
Staging systems
Tumor staging is used to determine the extent of disease spread in patients:
- Solid tumors
- Local spread
- Through lymphatics (lymphogenic)
- Distant (hematogenic)
- Haemotological malignancies
- Tells something about the disease extent and influence on normal bone marrow function
Cancer staging is useful for:
- Planning treatment
- Estimating prognosis
- Identifying clinical trials/studies
- Making a comparison between institutes
- Communication
- Staging is a universal language
There is no unique staging system. However, most staging systems do consist of several common elements:
- Location of the primary tumor
- Tumor size and number of tumors
- Lymph node involvement
- Spread of cancer into the lymph nodes
- Cell type and tumor grade
- How closely the cancer cells resemble normal tissue
- Presence or absence of distant metastasis
In general, the higher the stage, the worse the prognosis.
TNM staging principles:
The TNM staging principles is the most used staging system for solid tumors:
- T-status: extent of the tumor
- T1-T4
- The larger the tumor, the higher the T
- Size of the tumor and locally organ involvement
- T1-T4
- N-status: regional lymph node involvement → absence or presence of metastasis
- N0: no lymph nodes are involved
- N1: 1 or 2 lymph nodes are involved
- N2: infra- or subclavicular lymph nodes are involved
- M-status: distant metastasis
- M0: absent
- M1: present
The rules per tumor differ → prefix modifiers can be useful:
- cTNM → c = clinical
- Before treatment
- Mostly based on imaging or physical examination
- pTNM → p = histopathological
- After surgery
- ypTNM → yp = pathological after pretreatment
- After chemotherapy, but before surgery
- There is a large difference between the c and p stage
- TNMx → x = not classified
- Nothing is known about the tumor
For instance, a PA report states the following:
- Ductal adenocarcinoma
- Grade 3
- Diameter: 1,2 cm
- Free excision marks
- ER+/PR+
- Her2-
- Senital node: 0/2 lymph nodes contain metastasis
The TNM classification is pT1N0Mx.
Stages of breast cancer:
Breast cancer has 5 different stages:
- Stage 0: in situ cancer
- Stage 1: localized cancer
- Stage 2: further local spread, also usually includes spread to the nearest lymph nodes
- Stage 3: usually indicates more extensive lymph node involvement
- Stage 4: always indicates distant spread
Stages of lung cancer:
Lung cancer has 4 stages:
- Stage I: primary tumor
- A small tumor in the lung
- Stage II: primary tumor + small lymph node involvement
- Stage III: primary tumor + lymph node metastasis
- Lymph nodes are present in the mediastinum
- Stage IV: primary tumor + lymph node metastasis + metastatic tumor in the other lung/pleural involvement
A 67-year-old man has a primary lung tumor in the left upper lobe without signs of invasion in the pleura. The diameter is 6,5 cm. A PET scan shows the following:
- Elevated uptake in the primary process and in the mediastinum left
- A few tumor cells in a PET positive lymph node in the mediastinum
- No other abnormalities
The patient has an adenocarcinoma of stage cT3N2M0.
Other staging systems:
Several other staging systems are:
- Ann arbor staging: for lymphomas
- Stage I: single lymph node region
- Stage II: one side of the diaphragm
- Stage III: both sides of the diaphragm
- Stage IV: disseminated
- Duke’s classification: for colon cancer
- Breslow scale and Clark’s level: for melanomas
- Breslow scale: looks at the thickness of the melanoma
- Clark’s level: looks at the invasion in the epidermis and hypodermis
- FIGO: for gynaecological tumors, purely based on clinical investigation
- Cervic
- Vulva
- Endometrium
How to stage and when to stage:
Staging is done as follows:
- How: where the disease is expected to spread
- Knowledge of natural course of disease
- Knowledge of imaging modalities
- X-ray
- Ultrasound
- Endoscopies
- MRI
- CT-scan
- PET-scan
- When: the chance of spread determines the extensiveness of search
These moments differ per cancer type → treatment modalities are used to look for sites where the metastasis is most likely to occur:
- Sarcomas
- Usually no lymphogenic spread
- High risk for lung metastasis
- Pancreatic cancer
- High risk of liver metastasis early on
- Small cell lung cancer
- High chance of brain metastasis
Treatment of cancer
Treatment of cancer is based on:
- Characteristics of the tumor (grade)
- Stage of the tumor
- Intention of treatment
Terminology:
Important terminology used in treatment is:
- Curative/palliative/best supportive care
- Curative treatment: treatment aimed at cure
- Palliative treatment: treatment to alleviate symptoms → cure isn’t intended
- The palliative phase of a disease is not the same as the terminal phase
- Best supportive care: treatment in the terminal phase
- Adjuvant/neoadjuvant/primary/systemic
- Adjuvant: treatment given after primary treatment
- To treat micro-metastases
- Neoadjuvant: treatment given before primary treatment
- Sometimes called induction therapy
- Sometimes used to shrink the tumor so it can be removed easier
- Primary treatment: the main treatment modality
- Systemic treatment: affects a number of organs and tissues, or affects the body as a whole
- Chemotherapy, targeted therapy or immunotherapy
- Adjuvant: treatment given after primary treatment
- Concomitant/sequential/elective
- Concomitant: 2 modalities in the same time period
- Sequential: 2 modalities after each other
- Elective treatment/elective surgery
- Elective: local treatment of an area clinically negative but with high risk of involvement
- Elective surgery: prophylactive surgery of this area
- Pre-/per-/postoperative
- Preoperative: before the operation
- Peroperative: during the operation
- Postoperative: after the operation
Examples
Examples are:
- A patient with 2 tumorous lymph nodes in the axilla from left sided breast cancer
- Stage II cancer
- Treatment is curative
- A patient with liver metastases from colon cancer
- Stage IV cancer
- Treatment is palliative
- A patient with lung, liver and brain metastases from lung cancer
- Stage IV cancer
- Treatment is supportive care
Join with a free account for more service, or become a member for full access to exclusives and extra support of WorldSupporter >>
Mechanisms of Disease 2 2020/2021 UL
- Mechanisms of Disease 2 HC2: Cancer genetics
- Mechanisms of Disease 2 HC3: Cancer biology
- Mechanisms of disease 2 HC4: Cancer etiology
- Mechanisms of disease 2 HC5: Hereditary aspects of cancer
- Mechanisms of Disease 2 HC6: Cancer and genome integrity
- Mechanisms of Disease 2 HC7: Clinical relevance of genetic repair mechanisms
- Mechanisms of Disease 2 HC8: General principles: diagnostic pathology
- Mechanisms of Disease 2 HC9: Nomenclature and grading of cancer
- Mechanisms of Disease 2 HC10: General principles: metastasis
- Mechanisms of Disease 2 HC11: General principles: molecular diagnostics
- Mechanisms of Disease 2 HC12: How did cancer become the emperor of all maladies?
- Mechanisms of Disease 2 HC13: Heterogeneity in cancer
- Mechanisms of Disease 2 HC14: Cancer immunity and immunotherapy
- Mechanisms of Disease 2 HC15: Framework oncology and staging
- Mechanisms of Disease 2 HC16+17: Pharmacology I&II
- Mechanisms of Disease 2 HC18: Biomarkers for early detection of cancer
- Mechanisms of Disease 2 HC19: Surgical oncology
- Mechanisms of Disease 2 HC20: Radiation oncology
- Mechanisms of Disease 2 HC21: Medical oncology
- Mechanisms of Disease 2 HC22: Chemoradiation
- Mechanisms of Disease 2 HC23: Normal hematopoiesis
- Mechanisms of Disease 2 HC24: Diagnostics in hematology
- Mechanisms of Disease 2 HC25: Myeloid malignancies
- Mechanisms of Disease 2 HC26: Malignant lymphomas
- Mechanisms of Disease 2 HC27+28: Allogenic stem cell transplantation and donor lymphocyte infusion I&II
- Mechanisms of Disease 2 HC29: HLA & minor histocompatibility antigens
- Mechanisms of Disease 2 HC30: Changes in patients’ experiences
- Mechanisms of Disease 2 HC31: Targeted therapy and hematological malignancies
- Mechanisms of Disease 2 HC32+33: Primary hemostasis
- Mechanisms of Disease 2 HC34+35: Secondary hemostasis I&II
- Mechanism of Disease 2 HC36: Fibrinolysis and atherothrombosis
- Mechanisms of Disease 2 HC37: Cancer, coagulation and thrombosis
- Mechanisms of Disease 2 HC38: Bleeding disorders
- Mechanisms of Disease 2 HC39: Thrombosis

Contributions: posts
Spotlight: topics
Mechanisms of Disease 2 2020/2021 UL
Deze bundel bevat uitwerkingen van alle hoorcolleges, patientdemonstraties en eventuele (proef)tentamens van het blok Mechanisms of Disease 2 van de studie Geneeskunde aan de universiteit Leiden.
- Lees verder over Mechanisms of Disease 2 2020/2021 UL
- 1897 keer gelezen
JoHo can really use your help! Check out the various student jobs here that match your studies, improve your competencies, strengthen your CV and contribute to a more tolerant world
Add new contribution